ClinicalTrials.gg
CompletedNCT00835770ENDORSEUpdated Dec 31, 2020Results posted

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)

A Phase 3 interventional study of dimethyl fumarate and Placebo in Relapsing-Remitting Multiple Sclerosis, sponsored by Biogen. Completed at 246 sites in 34 countries. Open to participants aged 19 Years to 58 Years. Per ClinicalTrials.gov, last updated 2020-12-31.

Sponsored by Biogen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,736
Allocation
Randomized
Ages
19 Years to 58 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Dimethyl Fumarate · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
Largest of 22
1,736 · median 61
Started
2009
with 1 other
Phase 3
10 of 22
none open now
Registered
3rd of 22
by date
Lead sponsor
18 of 22
Biogen

Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, this one has the largest enrollment, is one of 2 that started in 2009, is one of 10 in phase 3, and was the 3rd registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About Dimethyl Fumarate

Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 19 Years to 58 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

The primary objective of this study is to evaluate the long-term safety profile of BG00012 (dimethyl fumarate). Secondary objectives of this study are to evaluate the long-term efficacy of BG00012 using clinical endpoints and disability progression, to evaluate further the long-term effects of BG00012 on multiple sclerosis (MS) brain lesions on magnetic resonance imaging (MRI) scans in participants who had MRI scans as part of Studies 109MS301 (NCT00420212) and 109MS302 (NCT00451451) and to evaluate the long-term effects of BG00012 on health economics assessments and the visual function test.

Read the detailed description

The initial BG00012 dosage for the extension study (240 mg BID or 240 mg TID) was the same as that used in the Phase 3 Studies 109MS301 (NCT00420212) and 109MS302 (NCT00451451). Subsequent to the initiation of this study, BG00012 was approved in several countries for the treatment of MS at a dose of 240 mg BID. For this reason, all participants continuing in this study will receive the currently marketed dose of 240 mg BID.

03

Conditions studied

  • Relapsing-Remitting Multiple Sclerosis

Keywords

  • relapsing
  • multiple sclerosis
  • remitting
  • oral
04

Who can participate

Ages eligible
19 Years to 58 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

-Subjects who participated in and completed as per protocol previous BG00012 clinical studies 109MS301 (NCT00420212) or 109MS302 (NCT00451451).

Key Exclusion Criteria:

  • Any significant change in medical history from 109MS301 or 109MS302 that would have excluded subject's participation from their previous study.
  • Subjects from 109MS301 or 109MS302 who discontinued oral study treatment due to an AE or due to reasons other than protocol-defined relapse/disability progression.
  • Subjects from 109MS301 or 109MS302 who discontinued study treatment due to disability progression or relapses and did not follow the modified visit schedule up to Week 96.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
1,736 participants (actual)

Study arms

  • Experimental
    BG00012 plus placebo

    In the first phase, participants will receive BG00012 240 mg (two 120 mg capsules) twice a day (BID) and 2 placebo capsules once a day. In the second phase participants will receive open-label BG00012 240 mg BID, for atleast 8 years.

    Drug: dimethyl fumarate · Drug: Placebo

  • Experimental
    BG00012

    In the first phase participants will receive BG00012 240 mg (two 120 mg capsules) three times a day (TID). In the second phase participants will receive open-label BG00012 240 mg BID for atleast 8 years.

    Drug: dimethyl fumarate

Interventions

  • BG00012 capsules

    Also known as: BG00012, Tecfidera, DMF

  • DrugPlacebo

    Capsules taken to maintain the blind in the 240 mg BID treatment group.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs)

    An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Day 1 up to Week 561

Secondary outcomes

  1. Percentage of Participants Who Had Relapses

    Relapses were defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours.

    Time frame: Day 1 up to Week 384

  2. Annualized Relapse Rate (ARR)

    The annualized relapse rate is calculated as the total number of relapses occurred during the period for all participants, divided by the total number of participant-years followed in the period.

    Time frame: Day 1 up to Week 384

  3. Change From Baseline in the Expanded Disability Status Scale (EDSS) at Week 384

    EDSS scale ranges from 0 (Normal neurological exam, no disability) to 10 (Death) in 0.5 unit increments that represent higher levels of disability. Scoring is based on an examination by a neurologist. Sustained disability progression was defined as at least a 1.0 point increase on the EDSS from a baseline EDSS ≥1.0 that was sustained for at least 24 weeks, or a 1.5 point increase on the EDSS from a baseline EDSS =0 that was sustained for at least 24 weeks.

    Time frame: Baseline, Week 384

  4. Number of Gadolinium (Gd)-Enhancing Lesions as Measured by Magnetic Resonance Imaging (MRI)

    The Gd-enhancing lesions was evaluated using MRI technique.

    Time frame: Baseline up to Week 288

  5. Volume of Gd-Enhancing Lesions as Measured by Magnetic Resonance Imaging (MRI)

    The Gd-enhancing lesions was evaluated using MRI technique.

    Time frame: Baseline up to Week 288

  6. Number of New or Newly Enlarging T2 Lesions as Measured by Magnetic Resonance Imaging (MRI)

    The T2 lesions was evaluated using MRI technique.

    Time frame: Baseline up to Week 288

  7. Volume of New or Newly Enlarging T2 Lesions as Measured by Magnetic Resonance Imaging (MRI)

    The T2 lesions was evaluated using MRI technique.

    Time frame: Baseline up to Week 288

  8. Number of T1 Hypointense Lesions as Measured by Magnetic Resonance Imaging (MRI)

    The T1 hypointense lesions was evaluated using MRI technique.

    Time frame: Baseline up to Week 288

  9. Volume of T1 Hypointense Lesions as Measured by Magnetic Resonance Imaging (MRI)

    The T1 hypointense lesions was evaluated using MRI technique.

    Time frame: Baseline up to Week 288

  10. Percent Change From Baseline in Brain Atrophy

    Brain atrophy was measured using magnetic resonance imaging (MRI) technique.

    Time frame: Baseline up to Week 288

  11. Percent Change From Baseline in Magnetization Transfer Ratio (MTR)

    Magnetization Transfer Ratio (MTR) was measured using MRI technique.

    Time frame: Baseline up to Week 288

  12. Change From Baseline in Short Form-36 Health Survey (SF-36®) at Week 384

    The SF-36 is a brief (36-item) scale reflecting the impact of both dysfunctions and general health perception the questionnaire measures: 1.physical function (PF),2. role physical (RF),3. bodily pain (BP),4. role emotional (RE),5. social function (SF), 6. general health (GH),7. vitality (VT), 8. mental health (MH). Items 1-4 primarily contribute to the PCS score of the SF-36. Items 5-8 primarily contribute to the mental component summary (MCS) score of the SF-36. The questions related to each dimension are scored on a scale from 0 (worst score) to 100 (best score), with higher scores indicating better function.

    Time frame: Baseline, Week 384

  13. Change From Baseline in EuroQol 5 Dimensions Questionnaire (EQ-5D) Health Survey - EQ-5D Index Score at Week 384

    The EQ-5D is a generic health-related quality of life instrument consisting of 2 components, EQ-5D index score and EQ-VAS. The EQ-5D provides a profile of the participant's health state in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each dimension, the participant is instructed to indicate whether he or she has (1) "no problems", (2) "some problems", or (3) "severe problems". A positive change from baseline indicates improvement.

    Time frame: Baseline, Week 384

  14. Change From Baseline in EuroQol 5 Dimensions Questionnaire (EQ-5D) Health Survey - Visual Analog Scale (VAS) at Week 384

    The EQ-5D is a generic health-related quality of life instrument consisting of 2 components, EQ-5D index score and EQ-VAS. In EQ-VAS participants are asked to rate their current health on a 20 centimeter (cm) scale from 0 to 100 where 0 represents "worst imaginable health state" and 100 represents "best imaginable health state". A positive change from baseline indicates improvement.

    Time frame: Baseline, Week 384

  15. Change From Baseline in Visual Function Test Scores at Week 384

    Participants were tested using the contrast level of 100%, 2.5%, and 1.25% charts, and the scores were defined as the number of letters identified correctly for each chart (the maximum score was 60). Higher scores indicate better functioning. A positive change from baseline indicates better functioning.

    Time frame: Baseline, Week 384

07

Results

Posted Dec 31, 2020

Participant flow

Participants were enrolled at 298 investigative sites from 03 February 2009 to 08 November 2019.

Participant flow — Overall Study
MilestoneBG00012 240 mg BIDBG00012 240 mg TID
Started868868
Completed384375
Not completed484493
Withdrew: Ms relapse1723
Withdrew: Ms progression149
Withdrew: Adverse event113124
Withdrew: Lost to follow-up2219
Withdrew: Consent withdrawn144156
Withdrew: Investigator decision4242
Withdrew: Participant non-compliance119
Withdrew: Death46
Withdrew: Other115104
Withdrew: Other21

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (AEs)

An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

Time frame:
Day 1 up to Week 561
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs)
ParticipantsBG00012 240 mg BIDBG00012 240 mg TID
Number of Participants With Treatment-Emergent Adverse Events (AEs)824814
SecondaryPercentage of Participants Who Had Relapses

Relapses were defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours.

Time frame:
Day 1 up to Week 384
Reported as:
Number · percentage of participants
Percentage of Participants Who Had Relapses
percentage of participantsBG00012 240 mg BID (Prior BG00012 240 mg BID)BG00012 240 mg TID (Prior BG00012 240 mg TID)BG00012 240 mg BID (Prior BG00012 Matched Placebo)BG00012 240 mg TID (Prior BG00012 Matched Placebo)BG00012 240 mg BID (Prior Glatiramer Acetate [GA])BG00012 240 mg TID (Prior Glatiramer Acetate [GA])
Percentage of Participants Who Had Relapses404134363131
SecondaryAnnualized Relapse Rate (ARR)

The annualized relapse rate is calculated as the total number of relapses occurred during the period for all participants, divided by the total number of participant-years followed in the period.

Time frame:
Day 1 up to Week 384
Reported as:
Number · relapses per participant-years
Annualized Relapse Rate (ARR)
relapses per participant-yearsBG00012 240 mg BID (Prior BG00012 240 mg BID)BG00012 240 mg TID (Prior BG00012 240 mg TID)BG00012 240 mg BID (Prior BG00012 Matched Placebo)BG00012 240 mg TID (Prior BG00012 Matched Placebo)BG00012 240 mg BID (Prior Glatiramer Acetate [GA])BG00012 240 mg TID (Prior Glatiramer Acetate [GA])
Annualized Relapse Rate (ARR)0.1590.1790.2000.1990.1840.212
SecondaryChange From Baseline in the Expanded Disability Status Scale (EDSS) at Week 384

EDSS scale ranges from 0 (Normal neurological exam, no disability) to 10 (Death) in 0.5 unit increments that represent higher levels of disability. Scoring is based on an examination by a neurologist. Sustained disability progression was defined as at least a 1.0 point increase on the EDSS from a baseline EDSS ≥1.0 that was sustained for at least 24 weeks, or a 1.5 point increase on the EDSS from a baseline EDSS =0 that was sustained for at least 24 weeks.

Time frame:
Baseline, Week 384
Reported as:
Mean · score on a scale
Change From Baseline in the Expanded Disability Status Scale (EDSS) at Week 384
score on a scaleBG00012 240 mg BID (Prior BG00012 240 mg BID)BG00012 240 mg TID (Prior BG00012 240 mg TID)BG00012 240 mg BID (Prior BG00012 Matched Placebo)BG00012 240 mg TID (Prior BG00012 Matched Placebo)BG00012 240 mg BID (Prior Glatiramer Acetate [GA])BG00012 240 mg TID (Prior Glatiramer Acetate [GA])
Baseline2.44 ± 1.2512.43 ± 1.1442.50 ± 1.1352.54 ± 1.2182.57 ± 1.2492.68 ± 1.231
Change at Week 3840.28 ± 1.1600.26 ± 1.2130.37 ± 1.3280.53 ± 1.2780.39 ± 1.2170.49 ± 1.319
SecondaryNumber of Gadolinium (Gd)-Enhancing Lesions as Measured by Magnetic Resonance Imaging (MRI)

The Gd-enhancing lesions was evaluated using MRI technique.

Time frame:
Baseline up to Week 288
Reported as:
Mean · lesions
Number of Gadolinium (Gd)-Enhancing Lesions as Measured by Magnetic Resonance Imaging (MRI)
lesionsBG00012 240 mg BID (Prior BG00012 240 mg BID)BG00012 240 mg TID (Prior BG00012 240 mg TID)BG00012 240 mg BID (Prior BG00012 Matched Placebo)BG00012 240 mg TID (Prior BG00012 Matched Placebo)BG00012 240 mg BID (Prior Glatiramer Acetate [GA])BG00012 240 mg TID (Prior Glatiramer Acetate [GA])
Week 480.4 ± 1.870.4 ± 1.290.2 ± 0.660.3 ± 1.140.5 ± 1.190.4 ± 1.14
Week 960.4 ± 1.770.4 ± 1.280.1 ± 0.380.2 ± 0.820.6 ± 1.330.3 ± 0.73
Week 1440.3 ± 1.660.4 ± 1.300.2 ± 0.440.1 ± 0.290.5 ± 2.480.3 ± 1.59
Week 1920.4 ± 2.020.5 ± 1.850.5 ± 1.720.3 ± 0.960.2 ± 0.600.6 ± 2.01
Week 2400.5 ± 3.140.5 ± 2.290.2 ± 0.500.2 ± 0.510.2 ± 0.580.3 ± 0.75
Week 2880.2 ± 0.740.5 ± 1.810.1 ± 0.400.7 ± 2.760.0 ± 0.000.3 ± 0.77
SecondaryVolume of Gd-Enhancing Lesions as Measured by Magnetic Resonance Imaging (MRI)

The Gd-enhancing lesions was evaluated using MRI technique.

Time frame:
Baseline up to Week 288
Reported as:
Mean · millimeter cube (mm^3)
Volume of Gd-Enhancing Lesions as Measured by Magnetic Resonance Imaging (MRI)
millimeter cube (mm^3)BG00012 240 mg BID (Prior BG00012 240 mg BID)BG00012 240 mg TID (Prior BG00012 240 mg TID)BG00012 240 mg BID (Prior BG00012 Matched Placebo)BG00012 240 mg TID (Prior BG00012 Matched Placebo)BG00012 240 mg BID (Prior Glatiramer Acetate [GA])BG00012 240 mg TID (Prior Glatiramer Acetate [GA])
Baseline31.7 ± 179.2848.6 ± 205.4396.0 ± 260.79142.5 ± 459.7637.1 ± 138.8241.7 ± 116.55
Week 4859.6 ± 526.5170.0 ± 366.6318.8 ± 91.4725.3 ± 108.1942.5 ± 123.6742.7 ± 148.11
Week 9649.1 ± 245.1456.1 ± 271.2927.7 ± 204.8013.3 ± 67.0164.3 ± 183.1622.3 ± 60.83
Week 14444.1 ± 291.1447.0 ± 169.6818.8 ± 66.153.8 ± 25.0342.6 ± 142.5592.9 ± 397.69
Week 19239.1 ± 217.8954.5 ± 251.3145.8 ± 156.8819.9 ± 79.1912.0 ± 40.5655.1 ± 169.16
Week 24096.8 ± 650.0669.3 ± 374.6721.7 ± 77.8714.1 ± 45.2217.5 ± 46.1917.1 ± 48.41
Week 28818.2 ± 93.2853.1 ± 250.877.9 ± 30.09230.2 ± 1092.110.0 ± 0.0034.1 ± 102.87
SecondaryNumber of New or Newly Enlarging T2 Lesions as Measured by Magnetic Resonance Imaging (MRI)

The T2 lesions was evaluated using MRI technique.

Time frame:
Baseline up to Week 288
Reported as:
Mean · lesions
Number of New or Newly Enlarging T2 Lesions as Measured by Magnetic Resonance Imaging (MRI)
lesionsBG00012 240 mg BID (Prior BG00012 240 mg BID)BG00012 240 mg TID (Prior BG00012 240 mg TID)BG00012 240 mg BID (Prior BG00012 Matched Placebo)BG00012 240 mg TID (Prior BG00012 Matched Placebo)BG00012 240 mg BID (Prior Glatiramer Acetate [GA])BG00012 240 mg TID (Prior Glatiramer Acetate [GA])
Week 481.6 ± 4.072.2 ± 6.152.7 ± 4.962.4 ± 5.453.4 ± 6.572.1 ± 3.83
Week 963.4 ± 8.354.1 ± 10.013.8 ± 7.242.9 ± 6.784.9 ± 8.513.4 ± 5.13
Week 1444.2 ± 9.815.2 ± 10.014.0 ± 7.274.3 ± 10.125.7 ± 9.455.2 ± 9.68
Week 1925.8 ± 14.047.5 ± 15.145.6 ± 10.095.6 ± 14.195.5 ± 9.945.6 ± 13.35
Week 2407.4 ± 17.099.5 ± 20.338.2 ± 14.877.7 ± 17.896.8 ± 11.747.5 ± 16.76
Week 2888.2 ± 18.5312.4 ± 28.237.5 ± 13.8910.4 ± 22.058.9 ± 15.046.0 ± 8.90
SecondaryVolume of New or Newly Enlarging T2 Lesions as Measured by Magnetic Resonance Imaging (MRI)

The T2 lesions was evaluated using MRI technique.

Time frame:
Baseline up to Week 288
Reported as:
Mean · mm^3
Volume of New or Newly Enlarging T2 Lesions as Measured by Magnetic Resonance Imaging (MRI)
mm^3BG00012 240 mg BID (Prior BG00012 240 mg BID)BG00012 240 mg TID (Prior BG00012 240 mg TID)BG00012 240 mg BID (Prior BG00012 Matched Placebo)BG00012 240 mg TID (Prior BG00012 Matched Placebo)BG00012 240 mg BID (Prior Glatiramer Acetate [GA])BG00012 240 mg TID (Prior Glatiramer Acetate [GA])
Baseline10231.9 ± 11214.1710408.3 ± 12166.808883.7 ± 8570.1010806.3 ± 12060.0512628.9 ± 11258.6913044.4 ± 14608.50
Week 489951.9 ± 10750.159849.6 ± 10986.368992.1 ± 7952.1310114.5 ± 10121.6111160.7 ± 9565.5512979.0 ± 14415.86
Week 9610331.3 ± 11359.8110434.0 ± 12201.388645.2 ± 7787.609985.7 ± 10715.7311318.1 ± 9873.7313974.1 ± 15432.10
Week 1449930.1 ± 10686.2610280.7 ± 11324.588829.4 ± 7482.939792.3 ± 9842.2810188.5 ± 8064.0912949.7 ± 14036.15
Week 1929837.7 ± 10845.0410760.0 ± 11987.169077.6 ± 7794.5210576.3 ± 12029.2610421.9 ± 8773.4111671.5 ± 13124.47
Week 24010611.2 ± 11633.9511087.5 ± 12464.909711.1 ± 8709.4610591.4 ± 11613.2611009.9 ± 9551.9412254.4 ± 13732.10
Week 2889611.8 ± 9447.189800.8 ± 11279.848819.8 ± 8866.9010537.6 ± 10684.4711586.3 ± 9728.1910404.8 ± 12245.75
SecondaryNumber of T1 Hypointense Lesions as Measured by Magnetic Resonance Imaging (MRI)

The T1 hypointense lesions was evaluated using MRI technique.

Time frame:
Baseline up to Week 288
Reported as:
Mean · lesions
Number of T1 Hypointense Lesions as Measured by Magnetic Resonance Imaging (MRI)
lesionsBG00012 240 mg BID (Prior BG00012 240 mg BID)BG00012 240 mg TID (Prior BG00012 240 mg TID)BG00012 240 mg BID (Prior BG00012 Matched Placebo)BG00012 240 mg TID (Prior BG00012 Matched Placebo)BG00012 240 mg BID (Prior Glatiramer Acetate [GA])BG00012 240 mg TID (Prior Glatiramer Acetate [GA])
Week 480.8 ± 2.131.0 ± 2.371.8 ± 3.811.7 ± 3.712.0 ± 4.221.3 ± 2.64
Week 961.7 ± 3.631.9 ± 3.911.8 ± 3.332.1 ± 5.003.0 ± 5.851.9 ± 3.44
Week 1442.0 ± 4.612.8 ± 5.192.0 ± 3.692.6 ± 7.023.1 ± 6.202.9 ± 5.19
Week 1922.9 ± 7.033.4 ± 6.792.9 ± 5.123.8 ± 10.713.3 ± 6.743.0 ± 7.14
Week 2403.4 ± 8.254.8 ± 9.394.0 ± 7.524.9 ± 13.304.0 ± 8.064.2 ± 10.20
Week 2882.7 ± 5.725.9 ± 12.024.5 ± 7.383.6 ± 4.511.0 ± 1.105.6 ± 6.81
SecondaryVolume of T1 Hypointense Lesions as Measured by Magnetic Resonance Imaging (MRI)

The T1 hypointense lesions was evaluated using MRI technique.

Time frame:
Baseline up to Week 288
Reported as:
Mean · mm^3
Volume of T1 Hypointense Lesions as Measured by Magnetic Resonance Imaging (MRI)
mm^3BG00012 240 mg BID (Prior BG00012 240 mg BID)BG00012 240 mg TID (Prior BG00012 240 mg TID)BG00012 240 mg BID (Prior BG00012 Matched Placebo)BG00012 240 mg TID (Prior BG00012 Matched Placebo)BG00012 240 mg BID (Prior Glatiramer Acetate [GA])BG00012 240 mg TID (Prior Glatiramer Acetate [GA])
Baseline3640.1 ± 5598.313447.3 ± 4900.962754.2 ± 3552.303623.1 ± 5549.133204.3 ± 4221.553572.6 ± 4915.24
Week 483829.5 ± 5824.263715.5 ± 5112.212891.9 ± 3034.003936.0 ± 5271.893271.0 ± 4157.243743.3 ± 5374.24
Week 963841.2 ± 5682.743853.7 ± 5428.662921.0 ± 3327.933849.4 ± 5167.133510.4 ± 4672.803949.7 ± 5018.63
Week 1443767.4 ± 4969.234074.0 ± 5413.853145.6 ± 3366.274006.9 ± 5062.083499.2 ± 4198.504126.1 ± 5695.44
Week 1923834.9 ± 4942.194177.4 ± 5301.683385.4 ± 3575.444330.0 ± 5136.673592.0 ± 4069.394089.3 ± 4996.13
Week 2404038.6 ± 5145.854238.2 ± 5248.843406.4 ± 3936.733823.9 ± 4274.823503.4 ± 3933.754057.7 ± 5223.62
Week 2883603.3 ± 4394.603973.1 ± 5202.053350.6 ± 4140.344187.5 ± 4835.433264.9 ± 3639.912959.1 ± 3918.62
SecondaryPercent Change From Baseline in Brain Atrophy

Brain atrophy was measured using magnetic resonance imaging (MRI) technique.

Time frame:
Baseline up to Week 288
Reported as:
Mean · percent change
Percent Change From Baseline in Brain Atrophy
percent changeBG00012 240 mg BID (Prior BG00012 240 mg BID)BG00012 240 mg TID (Prior BG00012 240 mg TID)BG00012 240 mg BID (Prior BG00012 Matched Placebo)BG00012 240 mg TID (Prior BG00012 Matched Placebo)BG00012 240 mg BID (Prior Glatiramer Acetate [GA])BG00012 240 mg TID (Prior Glatiramer Acetate [GA])
Change at Week 48-1.206 ± 1.1006-1.263 ± 1.0848-1.487 ± 1.3086-1.320 ± 1.4021-1.496 ± 1.1316-1.414 ± 1.1882
Change at Week 96-1.372 ± 1.1382-1.500 ± 1.0893-1.589 ± 1.3630-1.775 ± 1.7191-1.883 ± 1.2383-1.810 ± 1.4556
Change at Week 144-1.708 ± 1.4109-1.876 ± 1.2604-2.139 ± 1.5884-2.353 ± 1.7897-2.386 ± 1.3168-2.252 ± 2.2124
Change at Week 192-2.138 ± 1.6831-2.117 ± 1.4000-2.230 ± 1.7755-2.476 ± 1.7062-2.645 ± 1.2284-2.417 ± 2.0486
Change at Week 240-2.313 ± 1.6309-2.253 ± 1.3721-2.271 ± 1.4817-2.593 ± 1.9043-2.249 ± 1.2985-2.790 ± 2.2188
Change at Week 288-2.216 ± 1.5744-2.271 ± 1.2193-2.470 ± 1.6757-2.849 ± 1.9648-2.657 ± 1.7051-2.496 ± 1.3699
SecondaryPercent Change From Baseline in Magnetization Transfer Ratio (MTR)

Magnetization Transfer Ratio (MTR) was measured using MRI technique.

Time frame:
Baseline up to Week 288
Reported as:
Mean · percent change
Percent Change From Baseline in Magnetization Transfer Ratio (MTR)
percent changeBG00012 240 mg BID (Prior BG00012 240 mg BID)BG00012 240 mg TID (Prior BG00012 240 mg TID)BG00012 240 mg BID (Prior BG00012 Matched Placebo)BG00012 240 mg TID (Prior BG00012 Matched Placebo)BG00012 240 mg BID (Prior Glatiramer Acetate [GA])BG00012 240 mg TID (Prior Glatiramer Acetate [GA])
Change at Week 48-0.325 ± 5.4932-0.383 ± 4.86211.034 ± 7.3548-0.567 ± 4.4766-0.081 ± 13.6416-0.334 ± 1.5103
Change at Week 96-0.427 ± 6.6493-0.532 ± 4.98801.630 ± 7.6584-0.947 ± 7.0771-4.269 ± 12.60650.215 ± 1.4270
Change at Week 144-0.042 ± 9.25480.509 ± 7.26921.525 ± 8.64211.411 ± 12.2825-4.460 ± 10.38873.119 ± 8.1676
Change at Week 1921.038 ± 10.86800.955 ± 8.61053.012 ± 9.38313.103 ± 13.00461.384 ± 15.76113.841 ± 10.8600
Change at Week 240-0.002 ± 15.61901.647 ± 8.30943.213 ± 9.66214.108 ± 13.81032.959 ± 16.83860.673 ± 25.9962
Change at Week 2880.002 ± 4.0206-0.391 ± 4.6415-0.666 ± 2.0741-0.622 ± 2.2922-0.466 ± 0.9410-1.114 ± 2.4539
SecondaryChange From Baseline in Short Form-36 Health Survey (SF-36®) at Week 384

The SF-36 is a brief (36-item) scale reflecting the impact of both dysfunctions and general health perception the questionnaire measures: 1.physical function (PF),2. role physical (RF),3. bodily pain (BP),4. role emotional (RE),5. social function (SF), 6. general health (GH),7. vitality (VT), 8. mental health (MH). Items 1-4 primarily contribute to the PCS score of the SF-36. Items 5-8 primarily contribute to the mental component summary (MCS) score of the SF-36. The questions related to each dimension are scored on a scale from 0 (worst score) to 100 (best score), with higher scores indicating better function.

Time frame:
Baseline, Week 384
Reported as:
Mean · score on a scale
Change From Baseline in Short Form-36 Health Survey (SF-36®) at Week 384
score on a scaleBG00012 240 mg BID (Prior BG00012 240 mg BID)BG00012 240 mg TID (Prior BG00012 240 mg TID)BG00012 240 mg BID (Prior BG00012 Matched Placebo)BG00012 240 mg TID (Prior BG00012 Matched Placebo)BG00012 240 mg BID (Prior Glatiramer Acetate [GA])BG00012 240 mg TID (Prior Glatiramer Acetate [GA])
Baseline: Physical Functioning Score68.48 ± 25.93871.78 ± 24.84969.67 ± 24.48167.97 ± 26.27969.10 ± 25.22668.20 ± 25.370
Change at Week 384: Physical Functioning Score0.73 ± 21.972-4.79 ± 24.641-7.37 ± 22.253-6.89 ± 23.194-6.19 ± 21.719-6.25 ± 28.350
Baseline: Role-Physical Score56.46 ± 41.25458.42 ± 41.28056.35 ± 40.89659.87 ± 41.74755.26 ± 40.39053.57 ± 42.029
Change at Week 384: Role-Physical Score3.20 ± 48.259-2.75 ± 47.283-10.00 ± 43.188-8.24 ± 53.177-12.21 ± 40.595-1.04 ± 54.568
Baseline: Bodily-Pain Score69.68 ± 25.58770.42 ± 24.68868.51 ± 26.16369.44 ± 26.01669.30 ± 25.76668.59 ± 26.102
Change at Week 384: Bodily-Pain Score1.32 ± 28.525-1.47 ± 25.779-2.92 ± 23.486-4.36 ± 25.935-3.60 ± 22.138-4.46 ± 33.297
Baseline: General Health Score53.99 ± 21.56355.44 ± 20.76854.45 ± 18.69052.42 ± 20.02851.21 ± 18.70752.58 ± 19.675
Change at Week 384: General Health Score0.87 ± 18.744-2.12 ± 20.595-2.28 ± 16.752-0.52 ± 22.035-5.64 ± 18.2701.21 ± 21.674
Baseline: Vitality Score50.48 ± 20.96652.21 ± 19.84250.63 ± 19.13050.64 ± 21.06951.30 ± 19.70350.33 ± 20.019
Change at Week 384: Vitality Score1.11 ± 19.857-0.73 ± 19.033-4.67 ± 17.9340.40 ± 20.822-6.71 ± 20.2361.03 ± 19.829
Baseline: Social Functioning Score71.46 ± 24.45171.53 ± 24.39469.67 ± 24.58172.23 ± 24.69969.02 ± 24.68869.53 ± 25.100
Change at Week 384: Social Functioning Score-2.16 ± 25.575-3.30 ± 24.912-5.69 ± 22.184-2.08 ± 27.724-10.76 ± 34.350-0.52 ± 25.780
Baseline: Role-Emotional Score64.87 ± 40.65365.57 ± 40.01562.86 ± 42.71562.61 ± 41.28060.29 ± 41.39364.26 ± 41.854
Change at Week 384: Role-Emotional Score0.43 ± 49.9500.47 ± 43.513-12.22 ± 42.5324.17 ± 44.656-13.18 ± 42.501-3.55 ± 48.769
Baseline: Mental Health Score65.01 ± 19.81866.24 ± 19.06065.42 ± 17.65865.15 ± 19.23362.30 ± 17.34763.61 ± 18.414
Change at Week 384: Mental Health Score1.32 ± 19.7152.31 ± 18.095-3.91 ± 19.8972.33 ± 17.524-0.29 ± 21.989-2.06 ± 20.066
Baseline: Mental Component Score45.40 ± 11.13045.63 ± 10.27245.13 ± 10.93245.31 ± 10.90744.00 ± 10.70245.03 ± 10.642
Change at Week 384: Mental Component Score0.05 ± 12.4150.87 ± 10.028-2.55 ± 10.3281.97 ± 10.657-2.59 ± 12.8950.08 ± 10.328
Baseline: Physical Component Score43.53 ± 9.88444.44 ± 10.04843.74 ± 9.73943.56 ± 10.26743.68 ± 10.35943.15 ± 10.091
Change at Week 384: Physical Component Score0.55 ± 9.373-1.94 ± 10.532-2.29 ± 8.929-3.25 ± 9.998-2.70 ± 8.860-1.59 ± 10.765
SecondaryChange From Baseline in EuroQol 5 Dimensions Questionnaire (EQ-5D) Health Survey - EQ-5D Index Score at Week 384

The EQ-5D is a generic health-related quality of life instrument consisting of 2 components, EQ-5D index score and EQ-VAS. The EQ-5D provides a profile of the participant's health state in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each dimension, the participant is instructed to indicate whether he or she has (1) "no problems", (2) "some problems", or (3) "severe problems". A positive change from baseline indicates improvement.

Time frame:
Baseline, Week 384
Reported as:
Mean · score on a scale
Change From Baseline in EuroQol 5 Dimensions Questionnaire (EQ-5D) Health Survey - EQ-5D Index Score at Week 384
score on a scaleBG00012 240 mg BID (Prior BG00012 240 mg BID)BG00012 240 mg TID (Prior BG00012 240 mg TID)BG00012 240 mg BID (Prior BG00012 Matched Placebo)BG00012 240 mg TID (Prior BG00012 Matched Placebo)BG00012 240 mg BID (Prior Glatiramer Acetate [GA])BG00012 240 mg TID (Prior Glatiramer Acetate [GA])
Baseline0.73 ± 0.2100.73 ± 0.2220.72 ± 0.2230.71 ± 0.2440.71 ± 0.2460.72 ± 0.189
Change at Week 3840.01 ± 0.2510.00 ± 0.233-0.07 ± 0.2690.00 ± 0.249-0.04 ± 0.253-0.03 ± 0.241
SecondaryChange From Baseline in EuroQol 5 Dimensions Questionnaire (EQ-5D) Health Survey - Visual Analog Scale (VAS) at Week 384

The EQ-5D is a generic health-related quality of life instrument consisting of 2 components, EQ-5D index score and EQ-VAS. In EQ-VAS participants are asked to rate their current health on a 20 centimeter (cm) scale from 0 to 100 where 0 represents "worst imaginable health state" and 100 represents "best imaginable health state". A positive change from baseline indicates improvement.

Time frame:
Baseline, Week 384
Reported as:
Mean · score on a scale
Change From Baseline in EuroQol 5 Dimensions Questionnaire (EQ-5D) Health Survey - Visual Analog Scale (VAS) at Week 384
score on a scaleBG00012 240 mg BID (Prior BG00012 240 mg BID)BG00012 240 mg TID (Prior BG00012 240 mg TID)BG00012 240 mg BID (Prior BG00012 Matched Placebo)BG00012 240 mg TID (Prior BG00012 Matched Placebo)BG00012 240 mg BID (Prior Glatiramer Acetate [GA])BG00012 240 mg TID (Prior Glatiramer Acetate [GA])
Baseline70.97 ± 18.46070.48 ± 19.99370.40 ± 17.63069.44 ± 19.90766.80 ± 18.84669.07 ± 20.094
Change at Week 384-0.48 ± 19.631-1.67 ± 18.855-7.24 ± 18.419-3.17 ± 22.003-1.71 ± 25.330-4.11 ± 16.270
SecondaryChange From Baseline in Visual Function Test Scores at Week 384

Participants were tested using the contrast level of 100%, 2.5%, and 1.25% charts, and the scores were defined as the number of letters identified correctly for each chart (the maximum score was 60). Higher scores indicate better functioning. A positive change from baseline indicates better functioning.

Time frame:
Baseline, Week 384
Reported as:
Mean · score on a scale
Change From Baseline in Visual Function Test Scores at Week 384
score on a scaleBG00012 240 mg BID (Prior BG00012 240 mg BID)BG00012 240 mg TID (Prior BG00012 240 mg TID)BG00012 240 mg BID (Prior BG00012 Matched Placebo)BG00012 240 mg TID (Prior BG00012 Matched Placebo)BG00012 240 mg BID (Prior Glatiramer Acetate [GA])BG00012 240 mg TID (Prior Glatiramer Acetate [GA])
Baseline: 100% Chart54.7 ± 7.9555.0 ± 7.8455.1 ± 7.2654.8 ± 7.1254.3 ± 8.2655.0 ± 6.73
Change at Week 384: 100% Chart-0.4 ± 6.76-1.9 ± 6.81-1.4 ± 8.48-1.2 ± 7.53-1.6 ± 8.05-0.7 ± 5.17
Baseline: 2.5% Chart32.4 ± 12.1732.6 ± 11.7632.4 ± 11.4232.3 ± 11.9931.8 ± 12.3631.7 ± 12.41
Change at Week 384: 2.5% Chart-2.4 ± 10.77-3.3 ± 10.43-1.5 ± 11.77-4.9 ± 11.14-4.0 ± 11.90-2.1 ± 9.86
Baseline: 1.25% Chart24.1 ± 12.4524.2 ± 12.2823.8 ± 12.1123.7 ± 12.9623.4 ± 11.7622.2 ± 13.25
Change at Week 384: 1.25% Chart-5.8 ± 13.39-6.0 ± 11.77-4.1 ± 13.04-7.4 ± 12.42-6.7 ± 13.78-5.0 ± 12.74

Adverse events

Collected over From start of the study up to follow-up (up to Week 561). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BG00012 240 mg BID5/868 (0.6%)279/868 (32.1%)779/868 (89.7%)
BG00012 240 mg TID6/868 (0.7%)272/868 (31.3%)767/868 (88.4%)
Most frequent serious events
Showing 10 of 362
Most frequent serious events
EventBG00012 240 mg BIDBG00012 240 mg TID
Multiple sclerosis relapseNervous system disorders116/868122/868
FallInjury, poisoning and procedural complications13/86818/868
Urinary tract infectionInfections and infestations10/8684/868
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/8688/868
CholelithiasisHepatobiliary disorders2/8687/868
PneumoniaInfections and infestations6/8681/868
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/8683/868
Myocardial infarctionCardiac disorders1/8685/868
Road traffic accidentInjury, poisoning and procedural complications4/8685/868
Tibia fractureInjury, poisoning and procedural complications1/8685/868
Most frequent other events
Showing 10 of 44
Most frequent other events
EventBG00012 240 mg BIDBG00012 240 mg TID
Multiple sclerosis relapseNervous system disorders324/868335/868
NasopharyngitisInfections and infestations220/868226/868
Urinary tract infectionInfections and infestations196/868164/868
FlushingVascular disorders170/868165/868
HeadacheNervous system disorders145/868131/868
Upper respiratory tract infectionInfections and infestations143/868136/868
Back painMusculoskeletal and connective tissue disorders125/868125/868
DiarrhoeaGastrointestinal disorders111/868118/868
ArthralgiaMusculoskeletal and connective tissue disorders97/868115/868
FatigueGeneral disorders100/868102/868

Baseline characteristics

Intent-to-Treat (ITT) population included participants who had entered study NCT00835770 and received at least one dose of study treatment. Data for ethnicity was not evaluated in the study.

Age, Continuous
Age, Continuous(years)BG00012 240 mg BIDBG00012 240 mg TIDTotal
Mean39.6 ± 8.9340.1 ± 9.2339.8 ± 9.08
Sex: Female, Male
Sex: Female, Male(Participants)BG00012 240 mg BIDBG00012 240 mg TIDTotal
Female6165961212
Male252272524
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BG00012 240 mg BIDBG00012 240 mg TIDTotal
White285309594
Black or African American101626
Asian8280162
Other322456
Not Reported Due To Confidentiality Regulations459439898
08

Study locations

246 sites
  • Research Site
    Birmingham, Alabama 35294, United States
  • Research Site
    Huntsville, Alabama 35801, United States
  • research Site
    Mesa, Arizona 85206, United States
  • Research Site
    Phoenix, Arizona 85013, United States
  • Research Site
    Loma Linda, California 92354, United States
  • Research Site
    Boulder, Colorado 80304, United States
  • Research Site
    Fort Collins, Colorado 80528, United States
  • Research Site
    North Haven, Connecticut 06473, United States
  • Research Site
    Washington, District of Columbia 20007, United States
  • Research Site
    Maitland, Florida 32751, United States
  • Research Site
    Miami, Florida 33136, United States
  • Research Site
    Naples, Florida 34102, United States
  • Research Site
    Sarasota, Florida 34239, United States
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    Atlanta, Georgia 30309, United States
  • Research Site
    Atlanta, Georgia 30327, United States
  • Research Site
    Evanston, Illinois 60201, United States
  • Research Site
    Fort Wayne, Indiana 46845, United States
  • Research Site
    Kansas City, Kansas 66160, United States
  • Research Site
    Wichita, Kansas 67206, United States
  • Research Site
    Shreveport, Louisiana 71103, United States
  • Research Site
    Baltimore, Maryland 21201, United States
  • Research Site
    Boston, Massachusetts 02135, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Farmington Hills, Michigan 48334, United States
  • Research Site
    Minneapolis, Minnesota 55414, United States
  • Research Site
    Chesterfield, Missouri 63017, United States
  • Research Site
    Saint Louis, Missouri 63104, United States
  • Research Site
    Albany, New York 12206, United States
  • Research Site
    Amherst, New York 14226, United States
  • Research Site
    Buffalo, New York 14203, United States
  • Research Site
    Patchogue, New York 11772, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Raleigh, North Carolina 27607, United States
  • Research Site
    Bellevue, Ohio 44811, United States
  • Research Site
    Cleveland, Ohio 44195, United States
  • Research Site
    Columbus, Ohio 43221, United States
  • Research Site
    Dayton, Ohio 45417, United States
  • Research Site
    Medford, Oregon 97504, United States
  • Research Site
    Portland, Oregon 97225, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Philadelphia, Pennsylvania 19140, United States
  • Research Site
    Pittsburgh, Pennsylvania 15213, United States
  • Research Site
    Rumford, Rhode Island 02916, United States
  • Research Site
    Cordova, Tennessee 38018, United States
  • Research Site
    Knoxville, Tennessee 37922, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Newport News, Virginia 23601, United States
  • Research Site
    Issaquah, Washington 98029, United States
  • Research Site
    Madison, Wisconsin 53792, United States
  • Research Site
    Kogarah, New South Wales 2217, Australia
  • Research Site
    New Lambton Heights, New South Wales 2305, Australia
  • Research Site
    Melbourne, Victoria 3084, Australia
  • Research Site
    Box Hill, 3128, Australia
  • Research Site
    Chatswood, 2067, Australia
  • Research Site
    Fitzroy, 3065, Australia
  • Research Site
    Geelong, 3220, Australia
  • Research Site
    Sydney, 2000, Australia
  • Research Site
    Graz, 8036, Austria
  • Research Site
    Linz, 4021, Austria
  • Research Site
    Vienna, 1090, Austria
  • Research Site
    Belarus, Gomel 246029, Belarus
  • Research Site
    Belarus, Vitebsk 210023, Belarus
  • Research Site
    Minsk, 220114, Belarus
  • Research Site
    Minsk, 220116, Belarus
  • Research Site
    Antwerpen, 2020, Belgium
  • Research Site
    Brugge, 8000, Belgium
  • Research Site
    Brussels, 1200, Belgium
  • Research Site
    Charleroi, 6000, Belgium
  • Research Site
    Damme, 8340, Belgium
  • Research Site
    Diepenbeek, 3590, Belgium
  • Research Site
    Hechtel-Eksel, 3940, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Lodelinsart, 6042, Belgium
  • Research Site
    Sint-Truiden, 3800, Belgium
  • Research Site
    Tuzla, 75000, Bosnia and Herzegovina
  • Research Site
    Ruse, 7002, Bulgaria
  • Research Site
    Sofia, 1113, Bulgaria
  • Research Site
    Sofia, 1309, Bulgaria
  • Research Site
    Sofia, 1431, Bulgaria
  • Research Site
    Lévis, Quebec G6V 3Z1, Canada
  • Research Site
    Edmonton, T6G 2G3, Canada
  • Research Site
    London, N6A 5A5, Canada
  • Research Site
    Montreal, H3A 2B4, Canada
  • Research Site
    Nova Scotia, B3H 4K4, Canada
  • Research Site
    Ottawa, K2G 6E2, Canada
  • Research Site
    Regina, S4T 7T1, Canada
  • Research Site
    Zagreb, 10000, Croatia
  • Research Site
    Brno, 656 91, Czechia
  • Research Site
    Jihlava, 586 33, Czechia
  • Research Site
    Moravska Ostrava, 702 00, Czechia
  • Research Site
    Olomouc, 775 20, Czechia
  • Research Site
    Opava, 746 01, Czechia
  • Research Site
    Ostrava - Vítkovice, 70300, Czechia
  • Research Site
    Prague, 128 08, Czechia
  • Research Site
    Prague, 150 06, Czechia
  • Research Site
    Teplice, 415 01, Czechia
  • Research Site
    Parnu, 80010, Estonia
  • Research Site
    Tallinn, 10138, Estonia
  • Research Site
    Tallinn, 10617, Estonia

Showing the first 100 of 246 sites across 34 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gold R, Arnold DL, Bar-Or A, Fox RJ, Kappos L, Chen C, Parks B, Miller C. Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE. Ther Adv Neurol Disord. 2020 May 12;13:1756286420915005. doi: 10.1177/1756286420915005. eCollection 2020. Erratum In: Ther Adv Neurol Disord. 2020 Oct 21;13:1756286420968357. doi: 10.1177/1756286420968357. PubMed 32426039 ↗
  • Mehta D, Miller C, Arnold DL, Bame E, Bar-Or A, Gold R, Hanna J, Kappos L, Liu S, Matta A, Phillips JT, Robertson D, von Hehn CA, Campbell J, Spach K, Yang L, Fox RJ. Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice. Neurology. 2019 Apr 9;92(15):e1724-e1738. doi: 10.1212/WNL.0000000000007262. Epub 2019 Mar 27. PubMed 30918100 ↗
  • Gold R, Giovannoni G, Phillips JT, Fox RJ, Zhang A, Marantz JL. Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies. Neurol Ther. 2016 Jun;5(1):45-57. doi: 10.1007/s40120-016-0042-8. Epub 2016 Mar 1. PubMed 26932146 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2009 to primary completion in Nov 2019, 129 months.

Results were first posted in Dec 2020, 1 year 1 month after primary completion.

Of 28 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 129 months is above that.

Counting every sponsor, half of 38 studies reached it within 48 months; a quarter within 27 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2009
First posted
Feb 4, 2009
StartActual
Feb 3, 2009
Primary completionActual
Nov 8, 2019
CompletionActual
Nov 8, 2019
Results first posted
Dec 31, 2020
Last update
Dec 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00835770
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Feb 4, 2009
Start date
Feb 3, 2009
Primary completion
Nov 8, 2019
Completion
Nov 8, 2019
Results posted
Dec 31, 2020
Last update
Dec 31, 2020

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dimethyl Fumarate

Start the discussion